Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.6.0.2
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Operating Costs and Expenses:      
General and administrative $ 10,143 $ 8,074 $ 6,013
Research and development 29,109 32,906 14,489
Total Operating Costs and Expenses 39,252 40,980 20,502
Loss from Operations (39,252) (40,980) (20,502)
Other Income (Expense):      
Change in fair value of warrant liability 11,412 (3,811) 620
Other income 0 0 95
Interest income 37 6 3
Total Other Income (Expense) 11,449 (3,805) 718
Net Loss (27,803) (44,785) (19,784)
Net Loss Attributable to Non-controlling Interest (548) (1,048) 0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries $ (27,255) $ (43,737) $ (19,784)
Loss Per Share - Basic and Dilutive $ (0.29) $ (0.54) $ (0.32)
Net Income (Loss) Per Share - Basic and Dilutive      
Weighted average number of shares outstanding during the period - Basic and Dilutive 94,290,436 80,705,692 61,945,356